Medtronic Ups 2027 Forecasts Amid Rising Heart Device Demand

Medtronic has revised its fiscal 2027 financial forecasts upward, attributing the change to a surge in demand for its heart devices used in complex cardiovascular procedures. The medical technology company now anticipates annual organic revenue growth between 7.25% and 7.75%, a notable increase from its previous projection of 6.75% to 7.25%.

Strategic Investments and Innovations

The company announced a significant investment of $80 million in Pi-Cardia, a heart-valve repair device manufacturer, with an option to acquire the company for $210 million. Additionally, Medtronic has invested $700 million in Cornerstone Robotics, securing rights to distribute a robotic surgical device outside the U.S. These strategic moves are part of Medtronic's efforts to focus on high-growth segments within the medical technology sector.

During a post-earnings call, CEO Geoff Martha expressed confidence in the company's performance, citing not only the strength of the recent quarter but also the broad contributions from new growth platforms. He highlighted the potential of Cornerstone's Sentire device, which complements Medtronic's existing Hugo robotic surgery system, particularly in emerging markets where soft tissue robotic surgery penetration remains below 1%.

Financial Performance and Market Trends

Medtronic's cardiovascular segment saw a 19.5% increase in quarterly sales, reaching $3.93 billion. This growth was primarily driven by an 88% surge in its pulsed field ablation portfolio, a technology used to treat irregular heart rhythms. The company's adjusted quarterly profit per share was reported at $1.45, surpassing analyst expectations of $1.39, on revenue of $9.76 billion against an anticipated $9.55 billion.

Financial Chief Thierry Pieton noted that the company received tariff refunds that nearly offset its duties paid within the quarter, although these potential future refunds have not been factored into the new outlook.

Martha emphasized Medtronic's steady merger and acquisition activity, focusing on segments with large patient pools and significant growth potential. This strategy aligns with the broader industry trend of adopting advanced medical technologies to meet increasing surgical demands.